CGEM News & Events

"T cell engagers have the potential to transform outcomes for people living with autoimmune diseases and cancer, and emerging clinical data underscore their promise as a compelling therapeutic modality. We look forward to sharing initial clinical data for CLN-978 and velinotamig throughout 2026. CD19 and BCMA are now well-validated autoimmune targets, and by addressing both, we aim to comprehensively treat more diseases and redefine standards of care for more patients with these two clinical-stage programs. Similarly, the early success of CLN-049 in AML further reinforces the remarkable promise of T cell engagers in many high unmet need disease settings across immunology and oncology," said Nadim Ahmed, President and CEO of Cullinan Therapeutics.

Shares of Cullinan Therapeutics (CGEM) are moving higher after UCB (UCBJF) announced an agreement to acquire privately held Candid Therapeutics. Cizutamig, Candid's lead investigational asset, is "positioned as a potential best in class BCMA TCE for autoimmune diseases," UCB said in a statement. Cullinan's lead autoimmune asset, CLN-978, is a CD19xCD3 bispecific T-cell engager being developed in lupus, rheumatoid arthritis, and Sjogren's disease. Shares of Cullinan are up 7%, or 97c, to $14.40 in morning trading.